We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Medical Solutions Becomes first UK Commercial Service Provider of Illumina DNA Sequencing and Genotyping Applications

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medical Solutions Becomes first UK Commercial Service Provider of Illumina DNA Sequencing and Genotyping Applications"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The Board of Medical Solutions plc has announced that it is implementing a new technology platform at its Nottingham laboratory that will help to broaden the Company’s offering.

Medical Solutions will become the UK’s first commercial service provider for these systems, which it will be sourcing from Illumina, Inc.


• Medical Solutions to offer both Illumina’s Genome Analyzer, a next generation DNA sequencing system and Infinium whole genome genotyping on the BeadStation platform;

• First commercial service provider of Illumina applications in the UK;

• Complete pipeline of histopathology to genomic services, including DNA extraction, biobanking, whole genome amplification and DNA sequencing in GLP, GCP and CPA accredited laboratories.

Adoption of Illumina’s DNA sequencing and genotyping platforms will complement Medical Solutions’ portfolio of diagnostic and contract research services ranging from cell and tissue to genomic analysis.

This further demonstrates the Company’s commitment to be a market leader in the UK for the provision of expert, quality laboratory services to the healthcare, pharma biotech and life science research sectors.

Dr Tom Weaver, Commercial Director for Medical Solutions said, "We selected the Illumina platforms because the data quality, reproducibility, flexibility and breadth of applications are, in our opinion, the best in the industry. This represents cutting edge technology capable of revealing an enormous volume of genetic information. Customers have already expressed significant interest in applications run on the Genome Analyzer and BeadStation platforms, and it is our intention to develop strategic partnerships with these early adopters, enabling them to take full advantage of the power of whole genome analysis by providing high-quality data in an accredited quality laboratory environment."